Antitumor effect of hippurate. An experimental study using various mouse tumor strains.
Hippurate had antitumor effects both in vitro and in vivo by killing dose-dependently the cells derived from Skalsky lymphoma, Németh-Kellner lymphoma, L-asparaginase sensitive 6C3HED Gardner lymphoma, and LP-2 plasmacytoma. There was no significant difference between the effect of hippurate and its maternal compound benzoate. Hippurate administered intraperitoneally twice a day at a dose of 1 g/kg body weight significantly inhibited the growth of solid 6C3HED Gardner lymphoma even in the case that the treatment was started when the tumors reached a weight of over 400 mg. It was concluded that benzoates could be an important endogenous group of substances with antitumor effects.
Spustová
V
V
Center of Clinical Pharmacology, Medical Bionics Research Institute, Bratislava, Czechoslovakia.
Oravec
C
C
D000818:Animals; D000970:Antineoplastic Agents; D001565:Benzoates / Q000494:pharmacology; D002460:Cell Line; D006626:Hippurates / Q000494:pharmacology*; D008223:Lymphoma / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D009368:Neoplasm Transplantation; D010865:Pilot Projects; D010954:Plasmacytoma / Q000473:pathology; D011897:Random Allocation; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000970:Antineoplastic Agents; D001565:Benzoates; D006626:Hippurates